P W Armstrong Selected Research

Infarction (Infarctions)

7/2002	Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
6/2001	Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
3/2001	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes.
10/2000	Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
6/2000	Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
4/2000	Adverse effects of corticosteroids on the cardiovascular system.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

P W Armstrong Research Topics

Disease

14	Myocardial Infarction 03/2005 - 01/2000
11	Acute Coronary Syndrome 07/2005 - 06/2000
7	Heart Failure 01/2020 - 06/2000
7	ST Elevation Myocardial Infarction 08/2009 - 09/2001
6	Infarction (Infarctions) 07/2002 - 04/2000
4	Hemorrhage 03/2005 - 08/2000
3	Ischemia 03/2005 - 10/2000
2	Shock 08/2009 - 01/2000
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2003 - 08/2000
2	Unstable Angina 07/2002 - 06/2000
2	Coronary Disease (Coronary Heart Disease) 10/2001 - 04/2001
1	Hemorrhagic Fever with Renal Syndrome (HFRS) 01/2020
1	Frailty 01/2020
1	Dyspnea (Shortness of Breath) 07/2011
1	Chest Pain (Chest Pains) 09/2003
1	Non-ST Elevated Myocardial Infarction 07/2002
1	Body Weight (Weight, Body) 12/2001
1	Thrombosis (Thrombus) 03/2001
1	Hyperkalemia 01/2001
1	Hypotension (Low Blood Pressure) 01/2001
1	Diabetes Mellitus 12/2000
1	Atherosclerosis 08/2000
1	Thrombocytopenia (Thrombopenia) 08/2000
1	Sudden Death 08/2000
1	Disease Progression 07/2000
1	Heart Rupture 04/2000
1	Cicatrix (Scar) 04/2000
1	Dyslipidemias (Dyslipidemia) 04/2000
1	Hypertension (High Blood Pressure) 04/2000
1	Heart Arrest (Cardiac Arrest) 03/2000
1	Cardiogenic Shock 01/2000

Drug/Important Bio-Agent (IBA)

5	Tissue Plasminogen Activator (Alteplase)FDA Link 09/2003 - 01/2000
4	Heparin (Liquaemin)FDA LinkGeneric 03/2005 - 03/2001
4	Streptokinase FDA Link 10/2000 - 03/2000
3	paragonIBA 07/2005 - 06/2001
3	Lisinopril (Prinivil)FDA LinkGeneric 12/2000 - 08/2000
2	(2S)- 2- (4- (((3S)- 1- acetimidoyl- 3- pyrrolidinyl)oxy)phenyl)- 3- (7- amidino- 2- naphtyl)propanoic acidIBA 03/2005 - 02/2004
2	Glycoproteins (Glycoprotein)IBA 10/2003 - 06/2001
2	Staphylococcus aureus auR protein (staphylokinase)IBA 09/2003 - 05/2000
2	Tenecteplase FDA Link 07/2003 - 12/2001
2	Eptifibatide (Integrilin)FDA Link 07/2002 - 06/2000
2	HirudinsIBA 12/2001 - 03/2001
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2001 - 12/2000
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2001 - 12/2000
2	Platelet Membrane GlycoproteinsIBA 08/2000 - 06/2000
1	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2011
1	Blood Glucose (Blood Sugar)IBA 08/2009
1	Factor Xa InhibitorsIBA 03/2005
1	Factor Xa (Coagulation Factor Xa)IBA 03/2005
1	Creatine Kinase (Creatine Phosphokinase)IBA 02/2004
1	MB Form Creatine KinaseIBA 02/2004
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 07/2003
1	Enoxaparin (Lovenox)FDA LinkGeneric 07/2003
1	TNK-tissue plasminogen activatorIBA 12/2001
1	FibrinIBA 12/2001
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2001
1	Indicators and Reagents (Reagents)IBA 11/2001
1	Troponin T (Troponin T1)IBA 06/2001
1	Trinitrotoluene (TNT)IBA 06/2001
1	LipidsIBA 04/2001
1	AntithrombinsIBA 03/2001
1	Thrombin FDA Link 03/2001
1	reteplase FDA Link 10/2000
1	Plasminogen Activators (Plasminogen Activator)IBA 10/2000
1	NitratesIBA 10/2000
1	CalciumIBA 10/2000
1	lotrafibanIBA 08/2000
1	EnzymesIBA 06/2000
1	GlucocorticoidsIBA 04/2000

Therapy/Procedure

8	Therapeutics 07/2011 - 06/2000
4	Percutaneous Coronary Intervention 08/2009 - 12/2001
4	Thrombolytic Therapy 12/2001 - 01/2000
3	Time-to-Treatment 11/2005 - 10/2000
2	Patient Readmission 01/2020 - 07/2011
2	Length of Stay 01/2003 - 10/2000
2	Aftercare (After-Treatment) 12/2001 - 03/2001
2	Secondary Prevention 10/2001 - 08/2000
1	Drug Therapy (Chemotherapy) 01/2020
1	Treatment Delay 11/2005
1	Drug Tapering 01/2001
1	Resuscitation 03/2000